Authors

• Tobias Else (ORCID: https://orcid.org/0000-0002-2262-0011)
• Ane B. Iversen (ORCID: https://orcid.org/0009-0000-9529-4870)
• Wei Fu (ORCID: https://orcid.org/0009-0006-0365-7704)
• Jodi K. Maranchie (ORCID: https://orcid.org/0000-0002-8534-9468)
• Othon Iliopoulos (ORCID: https://orcid.org/0000-0002-4444-6157)
• Stéphane Oudard (ORCID: https://orcid.org/0000-0003-0893-285X)
• Vivek Narayan (ORCID: https://orcid.org/0000-0002-8205-738X)
• Kathryn E. Beckermann (ORCID: https://orcid.org/0000-0002-4616-6140)
• Cynthia M. Goldberg (ORCID: https://orcid.org/0009-0003-3390-994X)
• W. Marston Linehan (ORCID: https://orcid.org/0000-0001-7373-3916)
• Yanfang Liu (ORCID: https://orcid.org/0000-0002-4091-7679)
• Eric Jonasch
• Ramaprasad Srinivasan
• Rodolfo F Perini
• Benjamin L Maughan

Institutions

• Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
• The University of Texas MD Anderson Cancer Center (US)
• University of Pittsburgh (US)
• Université Paris Cité (FR)
• University of Utah (US)
• University of Michigan (US)
• Huntsman Cancer Institute (US)
• Aarhus University Hospital (DK)
• Hôpital Européen Georges-Pompidou (FR)
• Hôpital Européen (FR)
• National Cancer Institute (US)
• Center for Cancer Research (US)
• University of Pennsylvania (US)
• Vanderbilt University Medical Center (US)

Publication Details

Journal

The Lancet Oncology

Published

2024-09-13

DOI

https://doi.org/10.1016/s1470-2045(24)00389-9

Citations

32

Primary Topic

Cancer, Hypoxia, and Metabolism

Type

article

Field-Weighted Citation Impact

9.12

Funders

• National Institutes of Health
• Merck Sharp and Dohme
• National Cancer Institute